Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Molecule Discovery Could Advance Drug Design

By Kenny Walter | October 12, 2018

Study co-author Sean Rafferty in the Nagib Lab, where chemists develop new molecules for drug development. Credit: Jeff Grabmeier

A team from The Ohio State University has created a new way to generate the molecules used to design new types of synthetic drugs.

The researchers were able to form reactive intermediates called ketyl radicals that could allow scientists to use catalysts to convert simple molecules into complex structures in one chemical reaction in a more sustainable and waste-free manner.

“The previous strategy for creating ketyl radicals is about a century old. We have a found a complementary way to access ketyl radicals using LED lights for the synthesis of complex, drug-like molecules,” David Nagib, co-author of the new study and assistant professor of chemistry and biochemistry at Ohio State, said in a statement.

The researchers focused on carbonyls—compounds that function as a common building blocks to create potential new drugs—that were “radicalized” to become more reactive. The radical carbonyls each contain an unpaired electron that is seeking its partner.

This unique composition enables the researchers to form new bonds to create complex, drug-like products.

Ketyl radical formation previously required strong, harsh substances called reductants, such as sodium and samarium, to act as catalysts. However, reductants are also toxic, expensive and incompatible with creating medicines.

To avoid using these types of reductants, the researchers used manganese as a catalyst that can be activated with a simple LED light.

“Manganese is very cheap and abundant, which makes it an excellent catalyst,” Nagib said. “Also, it allows us to access radicals by a complementary atom-transfer mechanism, rather than the classic electron-transfer mechanism.”

While being both cheap and abundant, manganese is also more selective in creating products with defined geometries, which allows them to fit into drug targets.

Chemists usually transform carbonyl compounds through polar two-electron reactions or by adding just one electron to form a ketyl group, which is often limited by the strong reductant supplying that electron.

However, the photoactivated manganese catalyst can temporarily pull the iodine away to leave a ketyl to couple with alkynes. The iodine then returns to one of the alkyne’s carbons to stabilize the product and then remain poised for further transformations.

The new process is also able to recycle the iodine atom used to make the radical carbonyls because products that are more functional are included.

The study was published in Science.      


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE